http://www.littlebear.us/wp-content/uploads/ITCI-Little-Bear-July-2015-FINAL-WORD-PDF.pdf
I didn’t read all of it but it seems very negative overall for the future of iti-007
http://www.littlebear.us/wp-content/uploads/ITCI-Little-Bear-July-2015-FINAL-WORD-PDF.pdf
I didn’t read all of it but it seems very negative overall for the future of iti-007
Didn’t understand really…???
Whatever it is, it’s from 2015, before the clinical trials.
yea true your right
It does make me concerned that 120mg is no better then placebo, but hey it might work for some people :s
Well after reading all of that, it sounds like it would still be nice to have it on the market as an option.
If I understood what I read correctly, it provides D2 receptor occupancy but at lower percentages than some other drugs. If some mental illness is a matter of D2 problems, then wouldn’t it make sense to have some more options about how much occupancy you want to try at first / shoot for?
And if D2 receptor occupancy is lower, then it seems to make sense that the PANSS decrease was also less significant - but this could be “just right” for certain people, since we’re all essentially Goldilocks trying all these different “porridge” dishes until we fight the right one.
From the investor perspective (which was the angle of the written piece), sure it probably won’t be raking in the billions. But from a patient perspective, it would still be nice to be able to try it, to see if one could manage on less D2 blockage and get less side effects. While unfortunately it wouldn’t work for everyone (but what med even does), it could probably help some people with compliance.